Can Suprefact be given every forth month instead of third month with the same effect on castration levels.

Suprefact1 Can Suprefact be administrated every forth month with good castration effect. - Suprefact1

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2011-004836-76-SE

Enrollment

200

Registered

2011-10-11

Start date

2012-01-25

Completion date

Unknown

Last updated

2012-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer that need hormone treatment by LHRH-agoniste. MedDRA version: 14.0 Level: LLT Classification code 10071119 Term: Hormone-dependent prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Interventions

Trade Name: Suprefact (Buserelin) Product Name: Suprefact Pharmaceutical Form: Implant

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patient with prostatecancer that is planed to treat with LHRH-agoniste. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 25 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 175

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Main Objective: To see if Buserelin can keep the patient on castration level of testosterone up to four month instead of three month that is the normal interval between administration of Buserelin. This would be an advantage for the patient as well as an economic saving for the society.;Secondary Objective: ;Primary end point(s): Testosterone level after 4 month. ;Timepoint(s) of evaluation of this end point: 4 month after first administration of Buserelin	—

Measure

Time frame

Main Objective: To see if Buserelin can keep the patient on castration level of testosterone up to four month instead of three month that is the normal interval between administration of Buserelin. This would be an advantage for the patient as well as an economic saving for the society.;Secondary Objective: ;Primary end point(s): Testosterone level after 4 month. ;Timepoint(s) of evaluation of this end point: 4 month after first administration of Buserelin

—

Secondary

Measure	Time frame
Secondary end point(s): None	—

Countries

Sweden

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026